Xiao-Long Fu
Overview
Explore the profile of Xiao-Long Fu including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
105
Citations
1538
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Zhang Z, Gao S, Hu Y, Chen X, Cheng C, Fu X, et al.
Adv Sci (Weinh)
. 2022 Sep;
9(32):e2203557.
PMID: 36117048
Organoids have certain cellular composition and physiological features in common with real organs, making them promising models of organ formation, function, and diseases. However, Matrigel, the commonly used animal-derived matrices...
12.
Yan F, Liu J, Chen M, Zhang Y, Wei S, Jin H, et al.
Neural Regen Res
. 2022 Jul;
18(1):183-188.
PMID: 35799540
Icariin, a major prenylated flavonoid found in Epimedium spp., is a bioactive constituent of Herba Epimedii and has been shown to exert neuroprotective effects in experimental models of Alzheimer's disease....
13.
Zhang C, Yu W, Zhang Q, Cai X, Feng W, Fu X
Radiother Oncol
. 2022 Jun;
173:313-318.
PMID: 35764192
Introduction: Postoperative radiotherapy (PORT) plays a highly controversial role in pathological N2 (pN2) non-small cell lung cancer (NSCLC) disease. Recent studies reveal that not all patients can benefit from PORT....
14.
Zhang Q, Cai X, Feng W, Yu W, Fu X
BMC Cancer
. 2022 Jan;
22(1):96.
PMID: 35065627
Background: To explore the maximum tolerated dose (MTD) and evaluate the safety of dose escalation using hypofractionated simultaneous integrated boost intensity-modulated radiotherapy (SIB-IMRT) concurrent with chemotherapy for unresectable stage III...
15.
Wang C, Gao L, Lyu C, Zhang Q, Zeng W, Fang W, et al.
Med Oncol
. 2022 Jan;
39(2):25.
PMID: 34982283
There are no optimal regimens for advanced thymic epithelial tumors (TETs) when frontline chemotherapy fails. In this study, we aimed to assess the activity of Bevacizumab in combination with a...
16.
Cao J, Fu Y, Fu X, Ren S, Liu Y
Analyst
. 2021 Dec;
147(2):247-251.
PMID: 34931211
Herein, a novel and facile dual-wavelength ratiometric electrochemiluminescence-resonance energy transfer (ECL-RET) sensor for hydrogen sulfide (HS) detection was constructed based on the interaction between S and Cd-doped g-CN nanosheets (NSs)....
17.
Zhang C, Hou R, Feng W, Fu X
Front Oncol
. 2021 Oct;
11:736892.
PMID: 34604073
Pathologic N2 non-small cell lung cancer (NSCLC) is prominently intrinsically heterogeneous. We aimed to identify homogeneous prognostic subgroups and evaluate the role of different adjuvant treatments. We retrospectively collected patients...
18.
Shen Y, Qian L, Ding Z, Luo Q, Zhao H, Xia W, et al.
Front Oncol
. 2021 Sep;
11:711206.
PMID: 34540678
Objective: Inflammation plays a crucial role in tumorigenesis and progression. Our purpose was to investigate the prognostic value of neutrophil-to-lymphocyte ratio (NLR), systemic inflammation response index (SIRI) and systemic immune-inflammation...
19.
Li Y, Liu J, Cai X, Li H, Cheng Y, Dong X, et al.
Crit Rev Oncol Hematol
. 2021 Sep;
167:103466.
PMID: 34508841
Neoadjuvant chemoradiotherapy followed by surgery has been established as the standard treatment for locally advanced esophageal cancer. For patients with complete regression after neoadjuvant chemotherapy, active surveillance rather than planned...
20.
Yu W, Fu X, Cai X, Sun M, Guo Y
J Gastrointest Oncol
. 2021 Jul;
12(3):991-1006.
PMID: 34295551
Background: This study aimed to identify potential biomarkers associated with locoregional recurrence in patients with esophageal squamous cell carcinoma (ESCC) after radical resection. Methods: We performed a quantitative proteomics analysis...